The GMRF Clinical Trials Unit has no Liver clinical trials recruiting. New NASH Clinical Study to commence recruiting shortly.
PROTOCOL: 337HNAS20011 (NATiV3) (PI: DR Darrell Crawford)
Protocol Title: A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis
Lay Title: A Phase 3 Study Evaluating Long-term Efficacy and Safety of Lanifibranor in Adult Patients With (NASH) and Fibrosis 2 (F2)/Fibrosis 3 (F3) Stage of Liver Fibrosis (NATiV3)
PROTOCOL: IVB001-01 (PI: DR Darrell Crawford) (No yet recruiting)
Protocol Title: A Randomised, Double-Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Sublingual TransT3-60 in the Treatment of Non-Alcoholic SteatoHepatitis (NASH)
Lay Title: A phase 2 clinical study to evaluate the efficacy, safety and tolerability of TransT3-60 vs placebo (a powder administered sublingually) in participants with Non-Alcoholic SteatoHepatitis (NASH)